{"id":130900,"date":"2021-08-30T07:00:00","date_gmt":"2021-08-30T07:00:00","guid":{"rendered":"https:\/\/icrowdnewswire.com\/?p=2906193"},"modified":"2021-08-30T07:00:00","modified_gmt":"2021-08-30T07:00:00","slug":"neuexcell-therapeutics-raises-10-million-series-pre-a-round-to-continue-its-company-growth","status":"publish","type":"post","link":"https:\/\/ipsnews.net\/business\/2021\/08\/30\/neuexcell-therapeutics-raises-10-million-series-pre-a-round-to-continue-its-company-growth\/","title":{"rendered":"NeuExcell Therapeutics Raises $10+ Million Series Pre-A Round To Continue Its Company Growth"},"content":{"rendered":"

\"\"<\/p>\n

State College, PA., August 30, 2021 (GLOBE NEWSWIRE) \u2013 NeuExcell Therapeutics (www.neuexcell.com<\/a>), a gene therapy company focusing on neurodegenerative diseases, has announced a $10+ million Series Pre-A financing round. The round was led by Co-Win Ventures, joined by other institutional investors YuanBio, Oriza Seed, Tsingyuan, and InnoAngel.<\/p>\n

\u201cWe are honored to have this highly reputable group of investors join us,\u201d stated Peter Tombros, Board Chair at NeuExcell Therapeutics. \u201cThe investors\u2019 experience and support will enable the Company to leverage our proprietary neuroregenerative gene therapy platform across multiple neurodegenerative indications. The strength of this financing validates the Company\u2019s strategy and further validates our science within the biotech industry.\u201d<\/p>\n

\u201cWe are so excited about the prospects of accelerating our innovative technology to bring effective therapies to millions of patients around the world,\u201d said Professor Gong Chen, the company\u2019s co-founder and chief scientific advisor. \u201cThere is a desperate need for breakthrough therapies like ours.\u201d<\/p>\n

\u201cWe view this as a great opportunity to invest in experienced leadership,\u201d stated Dr. Xin Huang, managing partner at Co-Win Ventures. \u201cNeuExcell\u2019s proprietary technology has the potential to serve as a platform to treat many neurodegenerative diseases, offering hope to groundbreaking new therapies to patients without adequate options today.\u201d<\/p>\n

With the closure of this successful Pre-A round, the Company welcomes Dr. Xin Huang and Jonathan Sun to the Board of Directors.<\/p>\n

About NeuExcell Therapeutics<\/h3>\n

NeuExcell is a privately held early-stage gene technology company, with its headquarters in Pennsylvania, USA, and Shanghai, China. Its mission is to improve the lives of patients suffering from neurodegenerative diseases and CNS injuries. Based upon the scientific work of Prof. Gong Chen, the Company has developed a potentially disruptive neural repair technology through astrocyte-to-neuron conversion in vivo<\/em> by introducing neural transcription factor(s) through adeno-associated virus (AAV)-based gene therapy. NeuExcell\u2019s pipeline covers major neurodegenerative diseases such as Stroke, Huntington\u2019s disease, Amyotrophic Lateral Sclerosis (ALS), Alzheimer\u2019s Disease, Parkinson\u2019s Disease, Traumatic Brain Injury, Spinal Cord Injury, and Glioma.<\/p>\n

About Co-Win Ventures<\/h3>\n

Founded in 2009, Co-Win Ventures is a dedicated early-stage investor in Healthcare and TMT, who values equality, transparency, sharing, and innovation. Co-Win\u2019s business network covers China and the USA. With a total AUM of about 1 billion USD, Co-Win aims to become the trusted partner for exceptional entrepreneurs to build breakthrough technologies and companies. Co-Win Ventures has backed over 140 portfolio companies including Cytek (NASDAQ: CTKB), Connect (NASDAQ: CNTB), Thrive (acquired by a Nasdaq listed company, EXAS), Taimei Technology, Genecast, Sinovation, and Aucta, outstanding leaders in their respective sub-sectors.<\/p>\n

\n

See Campaign: <\/strong>https:\/\/neuexcell.com\/<\/a>
Contact Information:<\/b>
Xi Qin, COO & CFO xiqin@neuexcell.com<\/a><\/p>\n

Tags:<\/b>
Menafn<\/a>, IPS<\/a>, Google News<\/a>, Financial Content<\/a>, ReleaseLive<\/a>, PR-Wirein<\/a>, Reportedtimes<\/a>, Extended Distribution<\/a>, iCN Internal Distribution<\/a>, English<\/a><\/p>\n<\/div>\n

\n

Contact Information:<\/h3>\n

Xi Qin, COO & CFO
xiqin@neuexcell.com<\/a><\/p>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

State College, PA., August 30, 2021 (GLOBE NEWSWIRE) – NeuExcell Therapeutics (www.neuexcell.com), a gene therapy company focusing on neurodegenerative diseases, has announced a $10+ million Series Pre-A financing round. The round was led by Co-Win Ventures, joined by other institutional investors YuanBio, Oriza Seed, Tsingyuan, and InnoAngel. “We are honored to have this highly reputable […] Continue Reading →<\/span><\/a><\/p>\n","protected":false},"author":291,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-130900","post","type-post","status-publish","format-standard","hentry","category-press-release"],"yoast_head":"\nNeuExcell Therapeutics Raises $10+ Million Series Pre-A Round To Continue Its Company Growth - Business<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ipsnews.net\/business\/2021\/08\/30\/neuexcell-therapeutics-raises-10-million-series-pre-a-round-to-continue-its-company-growth\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NeuExcell Therapeutics Raises $10+ Million Series Pre-A Round To Continue Its Company Growth - Business\" \/>\n<meta property=\"og:description\" content=\"State College, PA., August 30, 2021 (GLOBE NEWSWIRE) – NeuExcell Therapeutics (www.neuexcell.com), a gene therapy company focusing on neurodegenerative diseases, has announced a $10+ million Series Pre-A financing round. The round was led by Co-Win Ventures, joined by other institutional investors YuanBio, Oriza Seed, Tsingyuan, and InnoAngel. “We are honored to have this highly reputable […] Continue Reading →\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ipsnews.net\/business\/2021\/08\/30\/neuexcell-therapeutics-raises-10-million-series-pre-a-round-to-continue-its-company-growth\/\" \/>\n<meta property=\"og:site_name\" content=\"Business\" \/>\n<meta property=\"article:published_time\" content=\"2021-08-30T07:00:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/08\/NeuExcell-1.jpg\" \/>\n<meta name=\"author\" content=\"iCrowdNewswire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"iCrowdNewswire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ipsnews.net\/business\/2021\/08\/30\/neuexcell-therapeutics-raises-10-million-series-pre-a-round-to-continue-its-company-growth\/\",\"url\":\"https:\/\/ipsnews.net\/business\/2021\/08\/30\/neuexcell-therapeutics-raises-10-million-series-pre-a-round-to-continue-its-company-growth\/\",\"name\":\"NeuExcell Therapeutics Raises $10+ Million Series Pre-A Round To Continue Its Company Growth - Business\",\"isPartOf\":{\"@id\":\"https:\/\/ipsnews.net\/business\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ipsnews.net\/business\/2021\/08\/30\/neuexcell-therapeutics-raises-10-million-series-pre-a-round-to-continue-its-company-growth\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ipsnews.net\/business\/2021\/08\/30\/neuexcell-therapeutics-raises-10-million-series-pre-a-round-to-continue-its-company-growth\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/08\/NeuExcell-1.jpg\",\"datePublished\":\"2021-08-30T07:00:00+00:00\",\"author\":{\"@id\":\"https:\/\/ipsnews.net\/business\/#\/schema\/person\/bde271d5882ffdcb71d1a2a961b51fee\"},\"breadcrumb\":{\"@id\":\"https:\/\/ipsnews.net\/business\/2021\/08\/30\/neuexcell-therapeutics-raises-10-million-series-pre-a-round-to-continue-its-company-growth\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ipsnews.net\/business\/2021\/08\/30\/neuexcell-therapeutics-raises-10-million-series-pre-a-round-to-continue-its-company-growth\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ipsnews.net\/business\/2021\/08\/30\/neuexcell-therapeutics-raises-10-million-series-pre-a-round-to-continue-its-company-growth\/#primaryimage\",\"url\":\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/08\/NeuExcell-1.jpg\",\"contentUrl\":\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/08\/NeuExcell-1.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ipsnews.net\/business\/2021\/08\/30\/neuexcell-therapeutics-raises-10-million-series-pre-a-round-to-continue-its-company-growth\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ipsnews.net\/business\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NeuExcell Therapeutics Raises $10+ Million Series Pre-A Round To Continue Its Company Growth\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ipsnews.net\/business\/#website\",\"url\":\"https:\/\/ipsnews.net\/business\/\",\"name\":\"Business\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ipsnews.net\/business\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/ipsnews.net\/business\/#\/schema\/person\/bde271d5882ffdcb71d1a2a961b51fee\",\"name\":\"iCrowdNewswire\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ipsnews.net\/business\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/aa079ec4d87ad6117c9db7a1a2cde1607ee2f869010252c2d0af346f0047b325?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/aa079ec4d87ad6117c9db7a1a2cde1607ee2f869010252c2d0af346f0047b325?s=96&d=mm&r=g\",\"caption\":\"iCrowdNewswire\"},\"sameAs\":[\"https:\/\/heymuse.com\/ips\"],\"url\":\"https:\/\/ipsnews.net\/business\/author\/icrowdnewswire\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NeuExcell Therapeutics Raises $10+ Million Series Pre-A Round To Continue Its Company Growth - Business","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ipsnews.net\/business\/2021\/08\/30\/neuexcell-therapeutics-raises-10-million-series-pre-a-round-to-continue-its-company-growth\/","og_locale":"en_US","og_type":"article","og_title":"NeuExcell Therapeutics Raises $10+ Million Series Pre-A Round To Continue Its Company Growth - Business","og_description":"State College, PA., August 30, 2021 (GLOBE NEWSWIRE) – NeuExcell Therapeutics (www.neuexcell.com), a gene therapy company focusing on neurodegenerative diseases, has announced a $10+ million Series Pre-A financing round. The round was led by Co-Win Ventures, joined by other institutional investors YuanBio, Oriza Seed, Tsingyuan, and InnoAngel. “We are honored to have this highly reputable […] Continue Reading →","og_url":"https:\/\/ipsnews.net\/business\/2021\/08\/30\/neuexcell-therapeutics-raises-10-million-series-pre-a-round-to-continue-its-company-growth\/","og_site_name":"Business","article_published_time":"2021-08-30T07:00:00+00:00","og_image":[{"url":"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/08\/NeuExcell-1.jpg","type":"","width":"","height":""}],"author":"iCrowdNewswire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"iCrowdNewswire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/ipsnews.net\/business\/2021\/08\/30\/neuexcell-therapeutics-raises-10-million-series-pre-a-round-to-continue-its-company-growth\/","url":"https:\/\/ipsnews.net\/business\/2021\/08\/30\/neuexcell-therapeutics-raises-10-million-series-pre-a-round-to-continue-its-company-growth\/","name":"NeuExcell Therapeutics Raises $10+ Million Series Pre-A Round To Continue Its Company Growth - Business","isPartOf":{"@id":"https:\/\/ipsnews.net\/business\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ipsnews.net\/business\/2021\/08\/30\/neuexcell-therapeutics-raises-10-million-series-pre-a-round-to-continue-its-company-growth\/#primaryimage"},"image":{"@id":"https:\/\/ipsnews.net\/business\/2021\/08\/30\/neuexcell-therapeutics-raises-10-million-series-pre-a-round-to-continue-its-company-growth\/#primaryimage"},"thumbnailUrl":"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/08\/NeuExcell-1.jpg","datePublished":"2021-08-30T07:00:00+00:00","author":{"@id":"https:\/\/ipsnews.net\/business\/#\/schema\/person\/bde271d5882ffdcb71d1a2a961b51fee"},"breadcrumb":{"@id":"https:\/\/ipsnews.net\/business\/2021\/08\/30\/neuexcell-therapeutics-raises-10-million-series-pre-a-round-to-continue-its-company-growth\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ipsnews.net\/business\/2021\/08\/30\/neuexcell-therapeutics-raises-10-million-series-pre-a-round-to-continue-its-company-growth\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ipsnews.net\/business\/2021\/08\/30\/neuexcell-therapeutics-raises-10-million-series-pre-a-round-to-continue-its-company-growth\/#primaryimage","url":"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/08\/NeuExcell-1.jpg","contentUrl":"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/08\/NeuExcell-1.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/ipsnews.net\/business\/2021\/08\/30\/neuexcell-therapeutics-raises-10-million-series-pre-a-round-to-continue-its-company-growth\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ipsnews.net\/business\/"},{"@type":"ListItem","position":2,"name":"NeuExcell Therapeutics Raises $10+ Million Series Pre-A Round To Continue Its Company Growth"}]},{"@type":"WebSite","@id":"https:\/\/ipsnews.net\/business\/#website","url":"https:\/\/ipsnews.net\/business\/","name":"Business","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ipsnews.net\/business\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/ipsnews.net\/business\/#\/schema\/person\/bde271d5882ffdcb71d1a2a961b51fee","name":"iCrowdNewswire","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ipsnews.net\/business\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/aa079ec4d87ad6117c9db7a1a2cde1607ee2f869010252c2d0af346f0047b325?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/aa079ec4d87ad6117c9db7a1a2cde1607ee2f869010252c2d0af346f0047b325?s=96&d=mm&r=g","caption":"iCrowdNewswire"},"sameAs":["https:\/\/heymuse.com\/ips"],"url":"https:\/\/ipsnews.net\/business\/author\/icrowdnewswire\/"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts\/130900","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/users\/291"}],"replies":[{"embeddable":true,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/comments?post=130900"}],"version-history":[{"count":1,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts\/130900\/revisions"}],"predecessor-version":[{"id":130901,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts\/130900\/revisions\/130901"}],"wp:attachment":[{"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/media?parent=130900"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/categories?post=130900"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/tags?post=130900"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}